COVID-19 Response at Fishpond.com.au

Read what we're doing...

Schizophrenia
By

Rating

Product Description
Product Details

Promotional Information

To date, progress has been painfully slow in revealing pathogenic mechanisms of schizophrenia and developing effective treatments for many of its devastating symptoms. This state of affairs partly reflects the daunting genetic and neurobiological complexity of this syndrome, but also reflects the persistence of the outdated view that schizophrenia represents one or a few conditions and of reductive explanations that focus on a single gene or neurotransmitter. This forward-looking volume breaks down barriers in multiple fields relevant to schizophrenia and should do much to propel schizophrenia research forward. -- Steven Hyman, Stanley Center for Psychiatric Research, Broad Institute The multi-faceted and complex nature of schizophrenia makes an ideal topic for the distinctive Ernst Strungmann Forum 'treatment.' This fascinating volume captures the current excitement in this fast-moving area by summarizing the outcomes of compelling head-to-head discussions on provocative position papers provided by leading experts writing from a variety of clinical and preclinical perspectives. -- Trevor W. Robbins, Professor of Cognitive Neuroscience and Experimental Psychology and Director, Behavioural and Clinical Neuroscience Institute, University of Cambridge Schizophrenia is a timely, provocative, and forward-looking volume of scholarly presentations and spirited discussions by international experts in the field. It covers a broad and ambitious range of topics, from genetics and cell biology to environmental risk factors to clinical phenomenology and clinical interventions including those targeting the social milieu, and it does so with depth and insight. The chapters share a theme of challenging prevailing dogma and proposing potentially paradigm-shifting solutions. This is a state-of-the-art compilation and a highly recommended read for researchers and clinicians interested in cutting-edge thought on this critically important and rapidly evolving subject. -- Daniel R. Weinberger, Director and CEO, Lieber Institute for Brain Development; Professor, Departments of Psychiatry, Neurology, Neuroscience, and The Institute of Genetic Medicine, Johns Hopkins University School of Medicine

About the Author

Steven M. Silverstein is Director of the Division of Schizophrenia Research at University Behavioral HealthCare, Rutgers Biomedical and Health Services, Rutgers University. Bita Moghaddam is leading researcher in the field of neuropsychopharmacology. She is Chair of the Department of Behavioral Neuroscience and Ruth Matarazzo Professor at Oregon Health and Science University in Portland. Til Wykes is Professor of Clinical Psychology and Rehabilitation at Kings College London, Director of the National Institute for Health Research Mental Health Research Network, Codirector of the Service User Research Enterprise, and editor of the journal Mental Health. Steven M. Silverstein is Director of the Division of Schizophrenia Research at University Behavioral HealthCare, Rutgers Biomedical and Health Services, Rutgers University. Bita Moghaddam is leading researcher in the field of neuropsychopharmacology. She is Chair of the Department of Behavioral Neuroscience and Ruth Matarazzo Professor at Oregon Health and Science University in Portland. Til Wykes is Professor of Clinical Psychology and Rehabilitation at Kings College London, Director of the National Institute for Health Research Mental Health Research Network, Codirector of the Service User Research Enterprise, and editor of the journal Mental Health. Peter J. Uhlhaas is Professor for Early Detection and Intervention of Mental Disorders at the Department of Child and Adolescent Psychiatry, Charite - Universita tsmedizin Berlin.. Joshua A. Gordon is Director of the National Institute of Mental Health (NIMH). William A. Phillips is Emeritus Professor of Neuropsychology at the University of Stirling and Adjunct Fellow of the Frankfurt Institute for Advanced Studies. Karoly Nikolich is Consulting Professor in the Department of Psychiatry at Stanford University Medical School as well as Founder of Circuit Therapeutics and Chairman of Alkahest, two biotechnology companies that grew out of research done at Stanford.

Reviews

There is a wide agreement that schizophrenia remains poorly understood, and this book marvelously summarizes not only the clinical problem, but also the beginnings of a plan for solving it.

-Journal of Clinical Psychiatry

Ask a Question About this Product More...
Write your question below:
How Fishpond Works
Fishpond works with suppliers all over the world to bring you a huge selection of products, really great prices, and delivery included on over 25 million products that we sell. We do our best every day to make Fishpond an awesome place for customers to shop and get what they want — all at the best prices online.
Webmasters, Bloggers & Website Owners
You can earn a 5% commission by selling Schizophrenia: Evolution and Synthesis: Volume 13 (Strungmann Forum Reports) on your website. It's easy to get started - we will give you example code. After you're set-up, your website can earn you money while you work, play or even sleep! You should start right now!
Authors / Publishers
Are you the Author or Publisher of a book? Or the manufacturer of one of the millions of products that we sell. You can improve sales and grow your revenue by submitting additional information on this title. The better the information we have about a product, the more we will sell!
Item ships from and is sold by Fishpond World Ltd.
Back to top